This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0269881109105450v1 0269881109105450v2    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stanford, S C Articles by Gillman, P K Search for Related Content PubMed PubMed Citation Articles by Stanford, S C Articles by Gillman, P K Social Bookmarking                         What's this?

Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium

¹ Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
² Department of Anaesthetics, St George's Hospital, London, UK
³ PsychoTropical Research, Bucasia, Queensland, Australia

^* To whom correspondence should be addressed.

	Abstract

Abstract

In a previous case report, published in this journal, we described a post-operative delirium in a patient during recovery from parathyroidectomy. We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery. We offered several tentative explanations for this event, including an adverse interaction between paroxetine and other agent(s) used in the course of the anaesthesia. Recent developments in characterisation of serotonin toxicity have prompted us to re-examine the clinical details surrounding this life-threatening event. It is now known to be important that the patient was given methylene blue, pre-operatively, to enable visualisation of the parathyroid glands. Methylene blue has been found to be a potent inhibitor of monoamine oxidase (MAO), and several cases of serotonin toxicity have been reported recently following its administration. All these cases are consistent with the well-known risk of serotonin toxicity when drugs that augment serotonergic transmission are given in combination with an MAO inhibitor. Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia. It is also being studied for treatment of Alzheimer's disease and malaria. In this paper, we outline the pharmacology of methylene blue and the aetiology of serotonin toxicity to help prevent further unintentional co-administration of drugs that risk precipitating this life-threatening drug interaction.

Key Words: delirium, methylene blue, monoamine oxidase inhibitor, nitric oxide, parathyroidectomy, selective serotonin reuptake inhibitor, serotonin toxicity, toxic metabolic syndrome

First published on May 7, 2009, doi:10.1177/0269881109105450
This version was published on May 21, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?